Abstract 48P
Background
Primary tumor resection and metastasectomy are curative options in some pts with mCRC. However, there is still a paucity of data regarding clinical outcomes and risk factors after disease recurrence and second metastasectomy in these pts.
Methods
We retrospectively evaluated the clinical outcomes of pts with mCRC undergoing a second metastasectomy at Seoul National University Bundang Hospital. In addition, the risk factors for the outcomes were analyzed.
Results
Among 269 pts who had achieved a disease-free state after primary tumor resection and first metastasectomy, 94 pts (female, 39 pts) received a second metastasectomy after recurrence, between Jul. 2006 and Feb. 2019. The median age was 62 years (range, 34-78 years). The primary tumor location was right colon in 16 pts (17.0%), left colon in 46 pts (48.9%), and rectum in 32 pts (34.0%). Recurred sites were lung in 47 pts (50.0%), liver in 36 pts (38.3%), both lung and liver in 4 pts (4.3%), and non-lung/non-liver in 7 pts (7.4%). Among them, 89 pts (94.7%) achieved R0 resection, while 3 (3.2%) and 2 (2.1%) pts underwent R1/R2 resection, respectively. During a median follow-up of 86.6 months (range, 39.5-193.0 months), the 5-year OS was 67.2±4.9%. Multivariate analysis for OS showed that age ≥70 years (HR 3.27 [95% CI, 1.31-8.15], P=0.011), non-lung/non-liver metastasis (HR 4.04 [95% CI, 1.21-13.51], P=0.024) and lesion number ≥2 (HR 2.25 [95% CI, 1.12-4.54], P=0.023) were poor prognostic factors. Among R0 resected pts, the 5-year DFS was 42.8±5.3%. Multivariable analysis for DFS identified that primary rectal cancer (HR 0.45 [95% CI, 0.22-0.94], P=0.033) and disease-free interval (DFI) after first metastasectomy ≥12 months (HR 0.39 [95% CI, 0.21-0.71], P=0.002) were good predictive factors while non-lung/non-liver metastasis (HR 3.32 [95% CI, 1.21-9.11], P=0.020) was a poor predictive factor.
Conclusions
Pts who received the second metastasectomy had a long-term disease-free state and good OS. Our data suggest that the second metastasectomy should be considered if a pt has liver- and/or lung-limited metastasis of limited number and long DFI after the first metastasectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study
Presenter: Thorsten Goetze
Session: Poster viewing 02
50P - Linear tumor regression of rectal cancer in daily MRI during preoperative chemoradiotherapy: An insight of tumor regression velocity for personalized cancer therapy
Presenter: Sea-Won Lee
Session: Poster viewing 02
51P - Efficacy and safety of sintilimab as first-line therapy in patients with microsatellite instability-high metastatic colorectal cancer: A real-world study
Presenter: Caiyun Nie
Session: Poster viewing 02
53P - Baseline PET/CT deep radiomics signature apply for identifying bevacizumab sensitivity of RAS-mutant colorectal cancer liver metastases patients
Presenter: Wenju Chang
Session: Poster viewing 02
54P - Efficacy of total neoadjuvant therapy (TNT) in rectal cancer: A meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: Poster viewing 02
55P - Biodegradable and biocompatible 3D-printed scaffolds loaded with chemotherapy drugs: A new horizon for treatment of colon cancer with diffuse intraperitoneal metastasis
Presenter: Amirhosein Kefayat
Session: Poster viewing 02
56P - Clinico-pathological profile of adolescent and young adult colorectal cancer patients: Multicentre collaborative registry data from India
Presenter: Soumya Surath Panda
Session: Poster viewing 02
57P - V-set and immunoglobulin domain containing 1 (VSIG1): Gene vs protein expression in colorectal cancer tissue samples
Presenter: Simona Gurzu
Session: Poster viewing 02